Automate Your Wheel Strategy on OGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including OGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OGEN
- Rev/Share 0.0
- Book/Share 0.0076
- PB 467.0217
- Debt/Equity 18.552
- CurrentRatio 1.5147
- ROIC -2.6169
- MktCap 2526926.0
- FreeCF/Share -0.4197
- PFCF -0.3305
- PE -6.2225
- Debt/Assets 0.6602
- DivYield 0
- ROE -9.547
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A
Read More
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Published: March 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission of its Investigator's Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia. This milestone represents an important step in advancing ONP-002, a novel intranasal neurosteroid, as a potential treatment for mild traumatic brain injury (mTBI), commonly known as concussion.
Read More
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform
Read More
About Oragenics, Inc. (OGEN)
- IPO Date 2004-02-25
- Website https://www.oragenics.com
- Industry Biotechnology
- CEO Ms. Janet Huffman
- Employees 3